SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 26.33-8.6%Jan 16 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jackie who wrote (10239)5/28/1999 10:49:00 AM
From: aknahow  Read Replies (2) of 17367
 
I have a little list:

1.Newsletters that cover XOMA give more prominence and get more positive.

2. T.V. appearances by these letter writers more likely to mention XOMA.

3.Momentum players come in and also talk about XOMA to one another.

4.Details of P II psoriasis released.

5.Patent news.

6. 13D filed by one institution.

7. Iprex deal done.

8. Meningo trial unblinded.

9. Additional scientific presentations, publications.

10. Press articles on meningo results, good or bad.

11.T.V. coverage of same if results good.

12.Mycoprex deal.

13.More cell expression agreements.

14.Humanization agreements.

15.New "drug" taken into clinic.

16. Trauma trial information on DSMB meeting.

So there are lots of things out there that can and should keep getting XOMA some attention. But if the results of the meningotrial are not good some of the attention will not be positive.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News